Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 20,000 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 20,000 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $51.83, for a total transaction of $1,036,600.00. Following the completion of the sale, the insider owned 2,231 shares in the company, valued at approximately $115,632.73. This trade represents a 89.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

William Guyer also recently made the following trade(s):

• On Tuesday, April 7th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $40.97, for a total transaction of $819,400.00.
• On Friday, March 20th, William Guyer sold 11,767 shares of Corcept Therapeutics stock. The stock was sold at an average price of $36.01, for a total transaction of $423,729.67.
• On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67.

Corcept Therapeutics Stock Performance

CORT opened at $51.05 on Friday. The firm’s fifty day moving average is $40.09 and its two-hundred day moving average is $53.80. The firm has a market cap of $5.48 billion, a PE ratio of 145.86 and a beta of 0.36. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $91.00.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. During the same quarter last year, the business posted $0.17 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Equities analysts forecast that Corcept Therapeutics Incorporated will post 0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CORT. Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Wolfe Research upgraded shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a report on Thursday, March 26th. Piper Sandler raised their price objective on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Finally, HC Wainwright raised their price objective on shares of Corcept Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $74.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CORT. Torren Management LLC bought a new position in Corcept Therapeutics in the fourth quarter valued at $25,000. Advisory Services Network LLC bought a new position in Corcept Therapeutics in the third quarter valued at $25,000. Clearstead Advisors LLC grew its position in Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. bought a new position in Corcept Therapeutics in the fourth quarter valued at $31,000. Finally, Hantz Financial Services Inc. grew its position in Corcept Therapeutics by 113.7% in the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 524 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised multi-year earnings forecasts and increased near-term EPS estimates (including Q2/FY2026 and FY2027–FY2030), maintaining a “Buy” rating and a $75 price target — a major bullish analyst signal that supports higher valuation expectations.
• Positive Sentiment: Market reaction to Corcept’s Q1 update: although the quarter showed a loss, analysts and investors focused on management’s stronger 2026 outlook and new ALS-related data, which helped lift the stock earlier in the day. Article Title
• Positive Sentiment: Zacks Research upgraded CORT from “strong sell” to “hold,” a modestly positive change in sell-side sentiment that can reduce selling pressure. Zacks Research
• Neutral Sentiment: Q1 2026 earnings call transcript is available for investors parsing management commentary and forward guidance for signs of durable revenue growth or margin improvement. Earnings Call Transcript
• Negative Sentiment: Insider selling: William Guyer sold 20,000 shares at an average $51.83 on May 5, materially reducing his position (about a 90% cut), which can be read negatively by some investors. SEC filing: SEC Filing
• Negative Sentiment: Q1 results missed consensus on EPS and revenue came in below estimates — a near-term negative that likely contributed to volatile price action despite the upbeat outlook. (This is the earnings backdrop that makes today’s analyst upgrades and data releases pivotal.)

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.